How Investors Are Reacting To Agilent Technologies (A) Expanding PD-L1 Test Use And Launching New AI Partnership

Simply Wall St.06-16 18:28

Earlier in June 2026, Agilent Technologies announced FDA approval to expand use of its PD-L1 IHC 22C3 pharmDx diagnostic on the Dako Omnis platform across multiple additional cancer types, while also ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643759930?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530","is_english":true,"pubTime":"2026-06-16 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643759930","market":"us","top_or_hot":-1,"title":"How Investors Are Reacting To Agilent Technologies (A) Expanding PD-L1 Test Use And Launching New AI Partnership","media":"Simply Wall St.","content":"<div>\n<p>Earlier in June 2026, Agilent Technologies announced FDA approval to expand use of its PD-L1 IHC 22C3 pharmDx diagnostic on the Dako Omnis platform across multiple additional cancer types, while also ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-are-reacting-to-agilent-technologies-a-expandi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Agilent Technologies (A) Expanding PD-L1 Test Use And Launching New AI Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Agilent Technologies (A) Expanding PD-L1 Test Use And Launching New AI Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 18:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-are-reacting-to-agilent-technologies-a-expandi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in June 2026, Agilent Technologies announced FDA approval to expand use of its PD-L1 IHC 22C3 pharmDx diagnostic on the Dako Omnis platform across multiple additional cancer types, while also ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-are-reacting-to-agilent-technologies-a-expandi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PD","symbol_name":"PagerDuty, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-are-reacting-to-agilent-technologies-a-expandi","article_id":"2643759930","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-are-reacting-to-agilent-technologies-a-expandi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643759930","pubTimestamp":1781605729,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in June 2026, Agilent Technologies announced FDA approval to expand use of its PD-L1 IHC 22C3 pharmDx diagnostic on the Dako Omnis platform across multiple additional cancer types, while also revealing a collaboration with OpenAI and Boston Consulting Group to accelerate artificial intelligence deployment in its instruments, software, and services.\nThis combination of broader companion diagnostic use for KEYTRUDA and a company-wide push into applied AI could reshape how Agilent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PD":"PagerDuty, Inc.","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","ARTY":"ISHARES FUTURE AI & TECH ETF","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4567":"ESG概念","AIPO":"Defiance AI and Power Infrastructure ETF","BK4585":"ETF&股票定投概念","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","ISBC":"投资者银行","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","AGIX":"通用人工智能 ETF-AGIX","BK4588":"碎股","A":"安捷伦科技","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4211":"区域性银行","LU1543694498.USD":"法巴水资源基金RH MD Dis","BK4023":"应用软件","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"投资者对安捷伦科技(A)扩大PD-L1测试使用并启动新的人工智能合作伙伴关系有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"A":1.5,"AIPO":1.5,"PD":1.5,"AGIX":1.5,"ARTY":1.5,"CHAT":1.5},"content_text":"Earlier in June 2026, Agilent Technologies announced FDA approval to expand use of its PD-L1 IHC 22C3 pharmDx diagnostic on the Dako Omnis platform across multiple additional cancer types, while also revealing a collaboration with OpenAI and Boston Consulting Group to accelerate artificial intelligence deployment in its instruments, software, and services. This combination of broader companion diagnostic use for KEYTRUDA and a company-wide push into applied AI could reshape how Agilent supports oncologists and lab customers across both testing workflows and product development. We’ll now examine how Agilent’s new AI collaboration with OpenAI and Boston Consulting Group may influence its existing investment narrative. Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementAgilent Technologies Investment Narrative RecapTo own Agilent, you generally need to believe in steady demand for life science tools, growing high-margin recurring revenues, and disciplined cost control despite tariff and supply chain pressures. The latest PD-L1 expansion and AI collaboration look directionally positive for diagnostics and workflow efficiency, but do not materially change the near term focus on offsetting tariff-driven cost inflation and managing competitive intensity in core instruments. Among recent announcements, the FDA’s expanded approval of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform stands out, because it reinforces Agilent’s role in KEYTRUDA-related testing across more tumor types. That kind of clinically anchored diagnostic footprint can matter for the company’s core catalyst of driving higher recurring test volumes, even as broader risks around tariffs, funding pressure in Academia & Government, and capital replacement cycles remain in view. Yet investors should still be aware that rising tariff driven costs and supply chain complexity could... Read the full narrative on Agilent Technologies (it's free!)Agilent Technologies' narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029.Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, a 23% upside to its current price.Exploring Other PerspectivesA 1-Year Stock Price Chart Four members of the Simply Wall St Community currently place Agilent’s fair value between US$150.54 and US$166.26, illustrating how far personal models can differ. Set this against the risk that higher tariffs and supply chain complexity may keep pressuring margins, and you have several distinct viewpoints on how resilient Agilent’s earnings profile really is, which are worth comparing before you decide where you stand.Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 27% more than the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.Searching For A Fresh Perspective?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Uncover the next big thing with 23 elite penny stocks that balance risk and reward.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.Outshine the giants: these 14 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643759930","isCrawlerRequest":true}